The complete response letter, issued by the FDA, does not identify what deficiencies regulators found in ...

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

An expert discusses how in the first-line (1L) treatment of advanced unresectable hepatocellular carcinoma (uHCC) with tyrosine kinase inhibitors (TKIs) such as lenvatinib or sorafenib, proactive ...

Sorafenib, a multikinase inhibitor approved by the FDA for ... In non-small cell lung cancer (including HCC827-GR) that is resistant to dystonin inhibitors (TKI), the OST inhibitors maintain the ...

In the ICI+TKI group, the point of treatment initiation was defined ... only observed an improved PFS in HCC patients treated with cabozantinib plus atezolizumab versus sorafenib but not OS. Similarly ...

Objective Sorafenib is effective in hepatocellular carcinoma (HCC), but patients ultimately present disease progression. Molecular mechanisms underlying acquired resistance are still unknown. Herein, ...

School of Pharmaceutical Sciences, University of South China, Hengyang 410001, China Hengyang Medical School, University of South China, Hengyang, Hunan 410001, China School of Pharmaceutical Sciences ...

The median treatment-free remission was not reached. Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) may be able to safely discontinue tyrosine kinase ...

resulting in a significant progression-free survival benefit over sorafenib. At present, there is no clear evidence of superiority of either sequence (TKI–TKI or TKI–mTOR) based on both ...

An expert discusses how first-line (1L) systemic therapy for unresectable hepatocellular carcinoma (uHCC) has evolved significantly from sorafenib monotherapy to include combination approaches such as ...